1. NIH Consensus Development Panel on impotence. JAMA 1993; 270: 83-90.
2. Feldman HA e coll. Impotence and its medical and psychosocial correlates: results of the Massachussets Male Aginf Stdy. J Urol 1994; 151: 54-61.
3. Araujo AB e coll. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from Massachussets Male Aging Study. Psychosom Med 1998; 60: 458-465.
4. Rajfer J e coll. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic; noncholinergic neurotrasmission. N Engl J Med 1992; 326: 90-94.
5. Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: 320-324.
6. Langtry HD, Markham A. Sildenafil: a review of its use in ertectile dysfunction. Drugs 1999; 57: 967-989.
7. Stief CG e coll. Effects of Sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000; 55: 146-150.
8. Goldstein I e coll. Oral Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
9. Padma-Nathan H e coll. Efficacy and safety of oral Sildenafil in treatment of erectile dysfunction: a double-bind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375-379.
10. Rendell MS e coll. Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421-426.
11. Conti CR e coll. Efficacy and safety of Sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83: 29C-34C.
12. Olsson AM, Persson CA. Efficacy and safety of Viagra (Sildenafil citrate) in men with cardiovascular disease and erectile dysfunction. Annual Meeting of the American College of Cardiology; 2000 Mar 14; Anaheim. Available from: http://www.medscape.com/medscape/cno/2001/ACC/Story.cfm?story id=1142 [Accessed 2001 Jan 31]
13. Derry FA e coll. Efficacy and safety of oral Sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998; 51: 1629-1633.
14. Jarow JP e coll. Clinical efficacy of Sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722-725.
15. Rosen RC e coll. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
16. Lowentritt BH e coll. Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999; 162: 1614-1617.
17. Zippe CD e coll. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241-245.
18. Morales A e coll. Clinical safety of oral Sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74.
19. Montorsi F e coll. Efficacy and safety of fixed dose oral Sildenafil in treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011-1018.
20. Virag R. Indications and early results of Sildenafil (Viagra) in erectile dysfunction. Urology 1999; 54: 1073-1077.
21. Moreira SG e coll. Side-effect profile of Sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56: 474-476.
22. Kaplan SA e coll. Safety and efficacy of Sildenafil in postmenopausal women with sexual dysfunction. Urology 1999; 53: 481-486.
23. Jackson G e coll. Effects of Sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C.
24. Bortolli M e coll. Effects of Sildenafil on esophageal motility of patients with idiopathic achalasia. Gastoenterology 2000; 118: 253-257.
25. Vobig MA e coll. Retinal side-effects of Sildenafil. Lancet 1999; 353: 375.
26. Zrenner E. No cause for alarm over retinal side-effects of Sildenafil. Lancet 1999; 353: 340-341.
27. Gonzalez CM e coll. Sildenafil causes a dose and time-dependent down regulation of phosphodiesterase type 6 expression in the rat retina. Int J Impot Res 1999; 11 suppl.1: 9-14.
28. Goldenberg MM. Safety and efficacy of Sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998; 20: 1033-1048.
29. Food and Drug Administration. Summary of reports of death in Viagra users received from marketing (late March) though mid-November 1998. Available from URL: htttp://www.fda.gov/cder/consumerinfo/viagra/safety3.htm [Accessed 2001 Jan 31].
30. Cheitlin MD e coll. Use of Sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999; 99: 168-177.
31. Cheitlin MD e coll. . ACC/AHA expert consensus document. Use of Sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273-282
32. Zusman RM e coll. Overall cardiovascular profile of Sildenafil citrate. Am J Cardiol 1999; 83: 35C-44C.
33. Kloner RA, Zusman RM. Cardiovascular effects of Sildenafil citrate and recommendations for its use. Am J Cardiol 1999; 84: 11-17.
34. Kloner RA. Cardiovascular risk and Sildenafil. Am J Cardiol 2000; 86 Suppl.: 57F-61F.
35. Speakman MT. Viagra and cardiovascular disease. J Cardiovasc Pharmacol Ther 1999; 4: 259-267.
36. Shakir S. IHD morbidity and mortality in a community-based cohort of Sildenafil users in England: phase 1 results (abstract) In: Velo G, Leone R, editors. Abstracts of the 8th Annual Meeting European Society of Pharmacovigilance; 2000 Sep 21-23; Verona Amsterdam: Elsevier, 2000: 14.
37. Webb DJ et al Sildenafil citrate and blood-pressure-lowering drugs: results of drug interacrtion studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C-28C.
38. Webb DJ . Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36: 25-31.
39. Geelen P et al Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000; 102: 275-277.
40. Awan GM e coll. Acute symptomatic atrial fibrillation after Sildenafil citrate therapy in a patient with hyperthrophic obstructive cardiomyopathy. Am J Med Sci 2000; 320: 69-71.
41. Pfizer US Prescribing information. Viagra ( Sildenafil citrate). Revised version January 2000. Available from URL: http://www.pfizer.com/htm(pi's/viagrapi.html [Accessed 2001 Jan 31]
42. Padma Nathan H. A new era in the treatment of erectile dysfunction. Am J Cardiol 1999; 84: 18-23
43. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, editors-in-chief. Goodman & Gilman's the pharmacological basis of therapeutics. New York (NY): Mc Graw-Hill, 1996; 199-248.
44. Hoffman BB. Adrenoceptor-blocking drugs. In : Kastzung BG, editor. Basic and clinical pharmacology. East Norwalk (CT): Appleton & Lange, 1995: 132-146.
45. Teloken C e coll. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998; 159: 122-124.
46. Kunelius P e coll. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence?: a prospective, randomised, controlled double-blind crossover study. Urology 1997; 49: 441-444.
47. Montorsi F e coll. Effects of yohimbine-trazodone on psychogenic impotence: a randomised double-blind, placebo controlled study. Urology 1994; 44: 732-736.
48. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomised clinical trials. J Urol 1998; 159; 433-436.
49. Hollister LE. Antidepressant agent. In: Katzung BG, editor. Basic and clinical pharmacology. East Norwalk (CT): Appleton & Lange, 1995; 448-459.
50. Lance R e coll. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 1995; 46: 117-120.
51. Meinhardt W e coll. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res 1997; 9: 163-165.
52. Heaton JPW e coll. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200-206.
53. Traish A e coll. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Impot Res 1998; 10: 215-223.
54. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988; 109: 162-163.
55. Zorgniotti AW: Experience with buccal phentolamine mesylate for impotence. Int J Impot Res 1994; 6: 37-41.
56. Becker AJ e coll. Oral phentolamine as treatment for erectile dysfunction. J Urol 1998; 159: 1214-1216.
57. Meinhardt W e coll. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. J Urol 1996; 8: 5-7.
58. Godschalk M e coll. Long - term efficacy of a new formulation of prostaglandin E-1 as treatment for erectile failure. J Urol 1996; 155; 915-917.
59. Buvat J et al. Double- bind multicenter study comparing alprostadil a-cyclodextrin with moxisylite chlorydrate in patients with chronic erectile dysfunction. J Urol 1998; 159: 116-119.
60. Linet OI e coll. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873-877.
61. Porst H. The rationale for prostaglandine E-1 in erectile failure; a survey of worldwide experience. J Urol 1996; 155: 802-815.
62. Padna-Nathan H e coll. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1-7
63. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187-192.
64. Ultiger RD. A pill for impotence. N Engl J Med 1998; 338: 1458-1459.
65. McMahon CG e coll. Treatment of intracorporeal injection nonresponse with Sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999; 162: 1992-19997; discussion 1997-1998.
66. Krane RJ e coll. Impotence. N Engl J Med 1989; 321: 1648-1659.
67. Warringtin JS e coll. In vitro biotrasformation of Sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Disp 2000; 28: 292-397.
68. Muirhead GJ e coll. Pharmacokinetic interactions between Sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.
69. Cohen JS. Should patients be given an initial low test dose of Sildenafil? Drug Saf 2001; 23: 1-9.
70. Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 1999; 44: 153-162.
71. Kassim AA e coll. Acute priapism associated with the use of Sildenafil in a patient with sickle cell trait.- Blood 2000; 95: 1878-1879.
72. Sur KR, Kane CJ. Sildenafil citrate-associated priapism. Urology 2000; 55: 950.